# FutuRX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/futurx

- Industry: Biotechnology
- Headquarters: Israel
- Website: www.futurx.co.il
- Total disclosed funding: $20M
- Latest round: Series B (May 29, 2019)
- Investors on record: 6

## About

Founded in 2014 and based in Ness Ziona, Israel, FutuRX is a biotechnology accelerator that develops novel modulators of protein degradation for cancer treatments. The company's drug modulates pathways related to proteostasis that offers an approach to the preferential targeting of cancer cells.

## Funding rounds

- Series B, May 29, 2019, $20M — Consensus Business Group, Pontifax Venture Capital, GF Securities, Arkin Capital, Quark Venture, RM Global Partners

## Investors

- Consensus Business Group — Series B
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series B
- GF Securities — Series B
- Arkin Capital (https://capitalatlas.ai/funds/arkin-capital) — Series B
- Quark Venture (https://capitalatlas.ai/funds/quark-venture) — Series B
- RM Global Partners (https://capitalatlas.ai/funds/rm-global-partners) — Series B